---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008231"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:32:37.874558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022

## Summary
- Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.
- Cash, equivalents and marketable securities $1.2B as of March 31, 2022 (vs $965.6M at Dec 31, 2021).
- R&D expenses $65.4M (excl. $155M Guide Therapeutics acquisition cost in Q1 2021); G&A $19.2M.
- BEAM-101 enrollment, BEAM-102 IND, and BEAM-201 IND all on track for second half of 2022.
- Initiated AUNT natural history study in sickle cell trait; appointed Manmohan Singh to exec leadership and Anne Marie Woodland as head of regulatory.

## SEC filing metadata
- accession: 0000950170-22-008231
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/0000950170-22-008231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/beam-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008231
- JSON: https://secwatch.observer/filing/0000950170-22-008231.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.